Dr. Giacomo Ruotolo has dedicated his scientific career to lipoprotein metabolism and prevention of ASCVD. He received his MD, board certification in Diabetes and Metabolic Diseases, and PhD in Clinical Pathophysiology in Italy. He has trained in the States with Barbara Howard and Virgil Brown at NIH and MedStar Research Institute, and in Sweden with Anders Hamsten at Karolinska Institute. Dr. Ruotolo has been the Head of the Lipid Clinic, and Lipoprotein Research Unit at San Raffaele Institute in Milan, and the Scientific Director of Penn Medical Lab at MedStar Research Institute. He is member of the Editorial Board of Journal of Clinical Lipidology, and co-organizer of the Annual ATVB HDL Workshop. He is Fellow of American Heart Association (FAHA), European Society of Cardiology (FESC) and National Lipid Association (FNLA). Before joining Eli Lilly & Company in January 2012 as Medical Fellow, Giacomo was the ASCVD Early Clinical Development Leader at AstraZeneca in Sweden.